Citadel Advisors LLC Buys New Position in Rapid Micro Biosystems, Inc. (NASDAQ:RPID)

Citadel Advisors LLC bought a new stake in shares of Rapid Micro Biosystems, Inc. (NASDAQ:RPID - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 72,024 shares of the company's stock, valued at approximately $65,000. Citadel Advisors LLC owned approximately 0.17% of Rapid Micro Biosystems as of its most recent SEC filing.

Separately, Renaissance Technologies LLC boosted its stake in Rapid Micro Biosystems by 122.9% in the fourth quarter. Renaissance Technologies LLC now owns 183,087 shares of the company's stock worth $165,000 after buying an additional 100,942 shares in the last quarter. 52.60% of the stock is currently owned by hedge funds and other institutional investors.

Rapid Micro Biosystems Stock Performance

RPID traded down $0.06 during midday trading on Friday, hitting $3.55. The stock had a trading volume of 87,105 shares, compared to its average volume of 194,285. Rapid Micro Biosystems, Inc. has a 1 year low of $0.58 and a 1 year high of $4.04. The business has a fifty day moving average of $2.84 and a 200 day moving average of $2.24. The company has a market cap of $155.60 million, a P/E ratio of -3.17 and a beta of 1.33.

Rapid Micro Biosystems (NASDAQ:RPID - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.01. Rapid Micro Biosystems had a negative return on equity of 48.05% and a negative net margin of 184.93%. The firm had revenue of $7.21 million during the quarter, compared to the consensus estimate of $6.63 million. On average, equities research analysts anticipate that Rapid Micro Biosystems, Inc. will post -1.1 earnings per share for the current year.

About Rapid Micro Biosystems

Rapid Micro Biosystems, Inc, a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services.